333388-03-7

Basic information

• Product Name: 4,6-Dichloro-2-(methylthio)-5-pyrimidineamine
• Synonyms: 4,6-Dichloro-2-(methylthio)-5-pyrimidineamine;4,6-Dichloro-2-(methylthio)pyrimidin-5-amine
• CAS NO: 333388-03-7
• Molecular Formula: C₅H₅Cl₂N₃S
• Molecular Weight: 210.0843
• Mol File: 333388-03-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,6-Dichloro-2-(methylthio)-5-pyrimidineamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloro-2-(methylthio)-5-pyrimidineamine(333388-03-7)
• EPA Substance Registry System: 4,6-Dichloro-2-(methylthio)-5-pyrimidineamine(333388-03-7)

Safety Data

• Hazardous Substances Data: 333388-03-7(Hazardous Substances Data)

Usage

Uses

Used in Water Treatment Systems:
4,6-Dichloro-2-(methylthio)-5-pyrimidineamine is used as a biocide and preservative in water treatment systems to prevent the growth of microorganisms, ensuring the cleanliness and safety of water supplies.
Used in Adhesives:
In the adhesives industry, 4,6-Dichloro-2-(methylthio)-5-pyrimidineamine is used as a preservative to prevent microbial contamination and spoilage, ensuring the quality and longevity of adhesive products.
Used in Coatings:
4,6-Dichloro-2-(methylthio)-5-pyrimidineamine is used as a biocide in coatings to protect against the growth of microorganisms that can cause discoloration, deterioration, and other issues in painted surfaces.
Used in Personal Care Products:
In personal care products, 4,6-Dichloro-2-(methylthio)-5-pyrimidineamine is used as a preservative to prevent microbial growth and maintain the safety and efficacy of these products. However, due to its potential health risks, its use in personal care products is strictly regulated in some countries.

Upstream product

• 1979-97-1 2-(methylthio)-5-nitropyrimidine-4,6-diol 
• 1979-98-2 4,6-dihydroxy-2-methylmercaptopyrimidine 
• 1979-96-0 4,6-dichloro-2-(methylthio)-5-nitropyrimidine 

Downstream Products

• 1196886-17-5 7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-2-(methylsulfonyl)-5-tosyl-5H-pyrrolo[3,2-d]pyrimidin-4-ol 
• 1196886-14-2 4-(benzyloxy)-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-2-(methylsulfonyl)-5-tosyl-5H-pyrrolo[3,2-d]pyrimidine 
• 1196886-12-0 4-(benzyloxy)-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-2-(methylthio)-5-tosyl-5H-pyrrolo[3,2-d]pyrimidine 
• 1196886-10-8 (E)-N-(4-(benzyloxy)-6-chloro-2-(methylthio)pyrimidin-5-yl)-N-(3-(4-methoxy-3,5-dimethylpyridin-2-yl)allyl)-4-methylbenzenesulfonamide 
• 1196886-08-4 N-(4-(benzyloxy)-6-chloro-2-(methylthio)pyrimidin-5-yl)-4-methylbenzenesulfonamide 
• 1196886-06-2 4-(benzyloxy)-6-chloro-2-(methylthio)pyrimidin-5-amine 
• 1000709-57-8 (7-Chloro-5-methylsulfanyl-thiazolo[5,4-d]pyrimidin-2-yl)-(2,6-dichloro-phenyl)-amine 

Relevant articles and documents

NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING

New pyrimidine derivatives together with a membrane penetrating agent, optionally with a detectable isotope and pharmaceutical composition for use in treatment or prevention of Gram-negative bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of Gram-negative biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives together with a membrane penetrating agent; for use as radiotracer in diagnosing or prognosing Gram-negative bacterial infection in a host mammal.

Synthesis of ticagrelor analogues belonging to 1,2,3-triazolo[4,5-d]pyrimidines and study of their antiplatelet and antibacterial activity

Based on the recent observation that the antiplatelet agent ticagrelor and one of its metabolite exert bactericidal activity against gram-positive bacteria, a series of 1,2,3-triazolo[4,5-d]pyrimidines structurally related to ticagrelor were synthesized and examined as putative antiplatelet and antibacterial agents. The aim was to assess the possibility of dissociating the two biological properties and to find novel 1,2,3-triazolo[4,5-d]pyrimidines expressing antiplatelet activity and devoid of in vitro antibacterial activity. The new compounds synthesized were known metabolites of ticagrelor as well as structurally simplified analogues. Some of them were found to express antiplatelet activity and to lose the antibacterial activity, supporting the view that the two activities were not necessarily linked.

HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS

New pyrimidine derivatives of formula (I), optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. New pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives for use as radiotracer in diagnosing or prognosing bacterial infection in a host mammal.

Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1

Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

Thiazolopyrimidine modulators of TRPV1

Certain TRPV1-modulating thiazolopyrimidine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.